Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Pipeline

Eight programmes, one shared platform

Internal and partnered programmes advancing from discovery through clinical evaluation. Stage assignments are reviewed quarterly by our scientific advisory board.

From nanoparticle design to manufacturing, vials and patient treatment

Being updated

Our programme table is being updated. Please check back soon or contact us for the latest status.

Track record

How we got here

  1. 2019

    Company founded

    Spun out of an academic nanomedicine lab with seed backing and three founding scientists.

  2. 2025

    First clinical readout

    BB-510 diagnostic panel entered clinical evaluation with a hospital network.

  3. 2026

    Two IND filings

    BB-101 and BB-207 progressing through IND-enabling toxicology.

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.